These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29318649)

  • 1. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression.
    Bauer DC; Black DM; Bouxsein ML; Lui LY; Cauley JA; de Papp AE; Grauer A; Khosla S; McCulloch CE; Eastell R;
    J Bone Miner Res; 2018 Apr; 33(4):634-642. PubMed ID: 29318649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained.
    Eastell R; Black DM; Lui LY; Chines A; Marin F; Khosla S; de Papp AE; Cauley JA; Mitlak B; McCulloch CE; Vittinghoff E; Bauer DC;
    J Bone Miner Res; 2021 Feb; 36(2):236-243. PubMed ID: 32916023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk.
    Eastell R; Vittinghoff E; Lui LY; Ewing SK; Schwartz AV; Bauer DC; Black DM; Bouxsein ML
    J Bone Miner Res; 2022 Nov; 37(11):2121-2131. PubMed ID: 36065588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis.
    Delmas PD; Munoz F; Black DM; Cosman F; Boonen S; Watts NB; Kendler D; Eriksen EF; Mesenbrink PG; Eastell R;
    J Bone Miner Res; 2009 Sep; 24(9):1544-51. PubMed ID: 19338427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study.
    Bønløkke SE; Rand MS; Haddock B; Arup S; Smith CD; Jensen JEB; Schwarz P; Hovind P; Oturai PS; Jensen LT; Møller S; Eiken P; Rubin KH; Hitz MF; Abrahamsen B; Jørgensen NR
    Osteoporos Int; 2022 Oct; 33(10):2155-2164. PubMed ID: 35729342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial.
    Bauer DC; Black DM; Garnero P; Hochberg M; Ott S; Orloff J; Thompson DE; Ewing SK; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1250-8. PubMed ID: 15231011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.
    Hochberg MC; Greenspan S; Wasnich RD; Miller P; Thompson DE; Ross PD
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1586-92. PubMed ID: 11932287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
    Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
    J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone Turnover Markers Are Not Associated With Hip Fracture Risk: A Case-Control Study in the Women's Health Initiative.
    Crandall CJ; Vasan S; LaCroix A; LeBoff MS; Cauley JA; Robbins JA; Jackson RD; Bauer DC
    J Bone Miner Res; 2018 Jul; 33(7):1199-1208. PubMed ID: 29923225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.
    Bauer DC; Garnero P; Hochberg MC; Santora A; Delmas P; Ewing SK; Black DM;
    J Bone Miner Res; 2006 Feb; 21(2):292-9. PubMed ID: 16418785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
    Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reference intervals for serum concentrations of three bone turnover markers for men and women.
    Michelsen J; Wallaschofski H; Friedrich N; Spielhagen C; Rettig R; Ittermann T; Nauck M; Hannemann A
    Bone; 2013 Dec; 57(2):399-404. PubMed ID: 24076251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in bone mass and bone turnover following tibial shaft fracture.
    Veitch SW; Findlay SC; Hamer AJ; Blumsohn A; Eastell R; Ingle BM
    Osteoporos Int; 2006; 17(3):364-72. PubMed ID: 16362144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
    Rogers A; Glover SJ; Eastell R
    Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women.
    Komi J; Heikkinen J; Rutanen EM; Halonen K; Lammintausta R; Ylikorkala O
    Gynecol Endocrinol; 2004 Mar; 18(3):152-8. PubMed ID: 15255284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone Turnover Status: Classification Model and Clinical Implications.
    Fisher A; Fisher L; Srikusalanukul W; Smith PN
    Int J Med Sci; 2018; 15(4):323-338. PubMed ID: 29511368
    [No Abstract]   [Full Text] [Related]  

  • 18. Bone turnover: Biology and assessment tools.
    Szulc P
    Best Pract Res Clin Endocrinol Metab; 2018 Oct; 32(5):725-738. PubMed ID: 30449551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone turnover biomarkers and risk of osteoporotic hip fracture in an Asian population.
    Dai Z; Wang R; Ang LW; Yuan JM; Koh WP
    Bone; 2016 Feb; 83():171-177. PubMed ID: 26555636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.